USA flag logo/image

An Official Website of the United States Government

DEVELOPMENT OF ALTERNATIVE AFFINITY CAPTURE REAGENTS FOR CANCE

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96225
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
N43CO201000072
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
AVANTGEN, INC.
AVANTGEN, INC. 10151 Pacific Mesa Blvd. SAN DIEGO, CA 92129-4571
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: DEVELOPMENT OF ALTERNATIVE AFFINITY CAPTURE REAGENTS FOR CANCE
Agency: HHS
Contract: N43CO201000072
Award Amount: $150,000.00
 

Abstract:

With the advances in proteomics, thousands of cancer biomarker candidates have been discovered. To fully validate these candidate cancer markers and eventually translate them into clinical use, it is essential to  establish a comprehensive, highly characterized and standardized collection of specific binding molecules directed against these cancer markers. AvantGen's technology platform for rapid isolation of recombinant  antibodies against human antigens is well suited for this need. In this Phase I study, antibodies against 10 cancer biomarkers will be isolated from an antibody yeast display library and their affinity and specificity will  be determined. The performances of the isolated antibodies will be comparable or better than those of commercially available monoclonal antibodies in terms of protein recognition, binding affinity, and detection  in ELISA-based assays and Western blot analysis. In addition, the cost of isolation and production of these recombinant antibodies will be significantly lower than monoclonal antibodies. Once the feasibility of our  approach in isolating and producing high affinity recombinant antibodies is demonstrated in Phase I, the process can be readily expanded for more cancer biomarkers. These affinity reagents will ultimately provide  a valuable resource of reproducible, highly qualified/characterized alternative protein capture reagents for the cancer research community.

Principal Investigator:

Xiaomin Fan
(858) 538-9866
xfan@avantgen.com
Small Business Information at Submission:

AVANTGEN, INC.
12240 KATYDID CIR SAN DIEGO, CA 92129-4571

EIN/Tax ID: 120215784
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No